Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Innate Pharma S.A. ADR (NQ: IPHA ) 2.090 -0.170 (-7.52%) Streaming Delayed Price Updated: 3:58 PM EDT, Jul 25, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Headline News about Innate Pharma S.A. ADR < Previous 1 2 3 4 Next > Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday June 10, 2024 Pre-market stock movers are worth diving into on Monday and we have all of the latest news worth knowing about this morning! Via InvestorPlace 12 Health Care Stocks Moving In Wednesday's After-Market Session April 03, 2024 Via Benzinga 12 Health Care Stocks Moving In Monday's Pre-Market Session April 01, 2024 Via Benzinga 12 Health Care Stocks Moving In Monday's After-Market Session March 11, 2024 Via Benzinga Earnings Scheduled For March 21, 2024 March 21, 2024 Companies Reporting Before The Bell • Creative Realities (NASDAQ:CREX) is expected to report quarterly earnings at $0.02 per share on revenue of $16.47 million. Via Benzinga 12 Health Care Stocks Moving In Tuesday's Pre-Market Session February 06, 2024 Via Benzinga 12 Health Care Stocks Moving In Thursday's Pre-Market Session October 05, 2023 Via Benzinga Regulatory Hurdle For Innate Pharma's Blood Cancer Studies October 05, 2023 The FDA has placed a clinical hold on Innate Pharma SA's (NASDAQ: IPHA) lacutamab Investigational New Drug (IND), leading to a pause in new patient enrollment in ongoing lacutamab trials IPH4102-201... Via Benzinga Exposures Product Safety Why Shares of Innate Pharma Jumped Thursday June 08, 2023 The company's collaboration agreement with Sanofi could soon pay off. Via The Motley Fool Tiziana Life Sciences Has Only Fully Human Anti-CD3 mAB In Clinical Studies, Could Be Poised To Improve Care For Patients With Severe Multiple Sclerosis April 19, 2023 Tiziana Life Sciences (NASDAQ: TLSA), a London-based biotechnology company, is developing a first-in-class drug, Foralumab. Foralumab is the only fully human anti-CD3 monoclonal antibody (mAb) at the... Via Benzinga 12 Health Care Stocks Moving In Monday's Pre-Market Session April 03, 2023 Via Benzinga Earnings Scheduled For March 23, 2023 March 23, 2023 Companies Reporting Before The Bell • Cognition Therapeutics (NASDAQ:CGTX) is likely to report earnings for its fourth quarter. Via Benzinga US Stocks Open Lower; Nasdaq Slides Over 100 Points December 27, 2022 U.S. stocks traded lower this morning, with the Nasdaq Composite dropping more than 100 points on Tuesday. Via Benzinga 12 Health Care Stocks Moving In Tuesday's Pre-Market Session December 27, 2022 Via Benzinga Why Shares of Chinese Companies Are Trading Higher? Here Are 55 Stocks Moving In Tuesday's Mid-Day Session December 27, 2022 Gainers Elys Game Technology, Corp. (NASDAQ: ELYS) shares jumped 147% to $0.4312. Elys Game Technology and Cloakbook DC have been granted license to open sportsbook in Washington, D.C. Via Benzinga 12 Health Care Stocks Moving In Monday's Pre-Market Session December 19, 2022 Via Benzinga After Five Years Of Collaboration, Sanofi & Innate Pharma Expand Oncology Pact With Additional Programs December 19, 2022 Via Benzinga Why Cosmos Health Shares Are Trading Lower By Around 60%? Here Are 79 Stocks Moving In Monday's Mid-Day Session December 19, 2022 Gainers Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) shares jumped 259% to $229.35 after the company announced resmetirom achieved both primary endpoints in NASH and liver fibrosis trial. Via Benzinga Why Innate Pharma Shares Are Trading Higher By 24%; Here Are 34 Stocks Moving Premarket December 19, 2022 Gainers AIM ImmunoTech Inc. (NYSE: AIM) shares rose 82.4% to $0.62 in pre-market trading. AIM ImmunoTech recently reported safety, tolerability and biological activity data for intranasal ampligen in... Via Benzinga Innate Pharma Highlights Early Lacutamab Data In Aggressive Form Of Blood Cancer December 12, 2022 Via Benzinga Why KnowBe4 Shares Jumped Over 28%; Here Are 79 Biggest Movers From Yesterday September 20, 2022 Gainers Ventoux CCM Acquisition Corp. (NASDAQ: VTAQ) shares jumped 54.6% to settle at $7.05 on Monday. Via Benzinga Why Virios Therapeutics Is Trading Lower By Over 71%, Here Are 55 Stocks Moving In Monday's Mid-Day Session September 19, 2022 Gainers MicroCloud Hologram Inc. (NASDAQ: HOLO) shares jumped 134.6% to $19.74. Via Benzinga 12 Health Care Stocks Moving In Monday's Pre-Market Session September 19, 2022 Via Benzinga Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday September 19, 2022 We're starting off the week with a breakdown of the biggest pre-market stock movers for Monday morning and the news behind them! Via InvestorPlace Why bluebird bio Is Trading Higher By Around 19%; Here Are 31 Stocks Moving Premarket September 19, 2022 Gainers FOXO Technologies Inc. (NYSE: FOXO) rose 161% to $10.50 in pre-market trading after dipping 52% on Friday. Via Benzinga Earnings Scheduled For September 15, 2022 September 15, 2022 Companies Reporting Before The Bell • Boqii Holding (NYSE:BQ) is estimated to report earnings for its first quarter. Via Benzinga Daily Biotech Pulse: Celyad Resumes Colorectal Cancer Trial, Setback For Otonomy, AstraZeneca Halts Phase 3 Head, Neck Cancer Trial August 01, 2022 Here's a roundup of top developments in the biotech space over the last 24 hours: Via Benzinga Why Revlon Shares Jumped 90%; Here Are 83 Biggest Movers From Yesterday August 02, 2022 Gainers Liberty TripAdvisor Holdings, Inc. (NASDAQ: LTRPB) shares jumped 187.3% to close at $48.03 on Monday after gaining around 18% on Friday. Via Benzinga This Biotechnology Stock Is Trading Lower By 77%, Here Are 62 Stocks Moving In Monday's Mid-Day Session August 01, 2022 Gainers Ontrak, Inc. (NASDAQ: OTRK) gained 102% to $1.3150. Ontrak is expected to report financial results for the second quarter on Tuesday, August 9, 2022. Via Benzinga AstraZeneca Cuts Innate-Partnered Phase 3 Trial In Head & Neck Cancer August 01, 2022 Via Benzinga < Previous 1 2 3 4 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.